DAX24.379 -0,2%Est505.652 +0,1%MSCI World4.337 +0,2%Top 10 Crypto17,00 +3,3%Nas22.781 -0,3%Bitcoin103.682 -0,4%Euro1,1732 -0,1%Öl64,36 +0,1%Gold3.886 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Plug Power A1JA81 Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T RENK RENK73 Palantir A2QA4J D-Wave Quantum A3DSV9 HENSOLDT HAG000 Novo Nordisk A3EU6F Siemens Energy ENER6Y BASF BASF11 Alibaba A117ME Lufthansa 823212 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht mit leichten Verlusten ins Wochenende -- Wall Street schließt uneins - Dow mit Rekord -- BMW steigert US-Absatz -- NVIDIA, Tesla, Palantir, Plug Power, IONOS, Boeing, Rumble im Fokus
Top News
Wieder keine Einigung im Kongress - 'Shutdown' bleibt bestehen Wieder keine Einigung im Kongress - 'Shutdown' bleibt bestehen
Die Highlights und Lowlights im TecDAX: Gewinner und Verlierer der KW 40 im Überblick Die Highlights und Lowlights im TecDAX: Gewinner und Verlierer der KW 40 im Überblick
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Immunic Aktie

Kaufen
Verkaufen
Immunic Aktien-Sparplan
0,8220 EUR -0,0220 EUR -2,61 %
BMN
0,9789 USD +0,0130 USD +1,35 %
nachbörslich
BTT
Immunic jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.80,93 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PHD4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4525EP1011

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIMUX

Immunic Aktien News

DatumMeistgelesen
EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in October
PR NewswireImmunic to Participate in Scientific and Investor Conferences in October
EQS GroupEQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Wer­bungImmunic-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireImmunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
PR NewswireImmunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in September
PR NewswireImmunic to Participate in Investor and Scientific Conferences in September
finanzen.netImmunic legte die Bilanz zum abgelaufenen Quartal vor
MotleyFoolImmunic (IMUX) Q2 Loss Widens 25%
EQS GroupEQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
PR NewswireImmunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
PR NewswireImmunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
EQS GroupEQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
PR NewswireImmunic to Participate in Investor, Scientific and Industry Conferences in June
finanzen.netImmunic: Quartalsergebnisse zum jüngsten Jahresviertel
EQS GroupEQS-News: Immunic to Participate in Scientific and Industry Conferences in May
PR NewswireImmunic to Participate in Scientific and Industry Conferences in May
EQS GroupEQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
PR NewswireImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
EQS GroupEQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS GroupEQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
finanzen.netImmunic: Bilanzvorlage zum letzten Quartal
EQS GroupEQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
PR NewswireImmunic, Inc. to Participate in Scientific and Industry Conferences in April
EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in March
PR NewswireImmunic to Participate in Scientific and Investor Conferences in March
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
PR NewswireImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in February
PR NewswireImmunic to Participate in Investor and Scientific Conferences in February
EQS GroupEQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
PR NewswireImmunic Highlights 2024 Accomplishments and Upcoming Milestones
EQS GroupEQS-News: Immunic, Inc. to Participate in Investor Conference in December
PR NewswireImmunic, Inc. to Participate in Investor Conference in December
EQS GroupEQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.